New combo therapy offers hope for Hard-to-Treat breast cancer
NCT ID NCT06434064
First seen Nov 01, 2025 · Last updated Jun 14, 2026 · Updated 31 times
Summary
This study tests whether combining tamoxifen (a hormone blocker) with a targeted form of chemotherapy (liposomal doxorubicin) can shrink tumors in people with advanced triple-negative breast cancer that has spread or cannot be removed by surgery. The trial enrolls 30 adults who have already tried at least two other treatments and have a specific TP53 gene change. The goal is to see how well the combination works and what side effects occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.